Abstract Introduction With the gradual improvement of medical treatment and nursing, more and more patients are successfully transferred out of the ICU. However, intensive care unit (ICU) survivors often experience long-term physical, cognitive, and psychological problems, and their family members also experience physical and psychological dysfunction, summarized as post-intensive care syndrome (PICS), affecting their health-related quality of life. Post-ICU follow-up can improve post-ICU syndrome in patients and their families, but the optimal mode of post-ICU follow-up remains uncertain. The purpose of this study was to build a follow-up model of ICU patients based on symptom management theory. Methods and analysis This study is a quasi-randomized controlled trial that will be conducted in multiple ICUs at one hospital in China, with patients enrolled from January 2024 to December 2024 and followed for 6 months. We expect to enroll 180 ICU patients. The primary outcome measure was the incidence of post-ICU syndrome (PICS) after ICU transfer, and the secondary outcome measure was the incidence of PCS-F, health economics evaluation, and patient/family satisfaction. Ethics and dissemination The protocol was approved by the research ethics committee of the Affiliated Hospital of Guizhou Medical University (2023 ethical review No. 061). The results will be published in peer-reviewed journals and presented at national and international scientific conferences to publicize the research to healthcare professionals, health service authorities and the public.

The authors have declared that no competing interests exist.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study has been approved by the research ethics committee of the Medical Science Ethics Committee of the Affiliated Hospital of Guizhou Medical University, and the approval number is: 2023 ethical review No. 061.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

Deidentified research data will be made publicly available when the study is completed and published.